;PMID: 6467378
;source_file_2941.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..175] = [t:42..175]
;2)section:[e:179..240] = [t:179..240]
;3)sentence:[e:244..388] = [t:244..388]
;4)sentence:[e:389..489] = [t:389..489]
;5)sentence:[e:490..623] = [t:490..623]
;6)sentence:[e:624..800] = [t:624..800]
;7)sentence:[e:801..967] = [t:801..967]
;8)sentence:[e:968..1091] = [t:968..1091]
;9)sentence:[e:1093..1214] = [t:1093..1214]
;10)sentence:[e:1215..1346] = [t:1215..1346]
;11)sentence:[e:1347..1451] = [t:1347..1451]
;12)section:[e:1455..1499] = [t:1455..1499]

;section 0 Span:0..36
;Cell Differ.  1984 Jun;14(2):135-44.
(SEC
  (FRAG (NNP:[0..4] Cell) (NNP:[5..11] Differ) (.:[11..12] .) (CD:[14..18] 1984)
        (CC:[19..26] Jun;14-LRB-) (CD:[26..27] 2) (-RRB-:[27..28] -RRB-)
        (::[28..29] :) (CD:[29..35] 135-44) (.:[35..36] .)))

;sentence 1 Span:42..175
;Retinoic acid-induced differentiation of cultured human neuroblastoma cells:
;a  comparison with phorbolester-induced differentiation.
;[98..111]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP
          (NML (JJ:[42..50] Retinoic) (NN:[51..55] acid))
          (HYPH:[55..56] -) (VBN:[56..63] induced))
        (NN:[64..79] differentiation))
      (PP (IN:[80..82] of)
        (NP (VBN:[83..91] cultured) (JJ:[92..97] human)
            (NN:[98..111] neuroblastoma) (NNS:[112..117] cells))))
    (::[117..118] :)
    (NP
      (NP (DT:[119..120] a) (NN:[122..132] comparison))
      (PP (IN:[133..137] with)
        (NP
          (ADJP (NN:[138..150] phorbolester) (HYPH:[150..151] -)
                (VBN:[151..158] induced))
          (NN:[159..174] differentiation))))
    (.:[174..175] .)))

;section 2 Span:179..240
;Pahlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T.
(SEC
  (FRAG (NNP:[179..186] Pahlman) (NNP:[187..188] S) (,:[188..189] ,)
        (NNP:[190..197] Ruusala) (NNP:[198..200] AI) (,:[200..201] ,)
        (NNP:[202..213] Abrahamsson) (NNP:[214..216] L,)
        (NNP:[217..225] Mattsson) (NNP:[226..228] ME) (,:[228..229] ,)
        (NNP:[230..237] Esscher) (NNP:[238..240] T.)))

;sentence 3 Span:244..388
;Cultured human SH-SY5Y neuroblastoma cells differentiated in the presence of 
;retinoic acid (RA) or 12-0-tetradecanoyl-phorbol-13-acetate (TPA).
;[267..280]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-HLN (VBN:[244..252] Cultured) (JJ:[253..258] human)
            (NN:[259..266] SH-SY5Y) (NN:[267..280] neuroblastoma)
            (NNS:[281..286] cells))
    (VP (VBD:[287..301] differentiated)
      (PP (IN:[302..304] in)
        (NP
          (NP (DT:[305..308] the) (NN:[309..317] presence))
          (PP (IN:[318..320] of)
            (NP
              (NP
                (NP (JJ:[322..330] retinoic) (NN:[331..335] acid))
                (NP (-LRB-:[336..337] -LRB-) (NN:[337..339] RA)
                    (-RRB-:[339..340] -RRB-)))
              (CC:[341..343] or)
              (NP
                (NP (NN:[344..381] 12-0-tetradecanoyl-phorbol-13-acetate))
                (NP (-LRB-:[382..383] -LRB-) (NN:[383..386] TPA)
                    (-RRB-:[386..387] -RRB-))))))))
    (.:[387..388] .)))

;sentence 4 Span:389..489
;In both  cases, the cells acquired long cell processes and the cell growth
;was partially  inhibited.
(SENT
  (S
    (S
      (PP (IN:[389..391] In)
        (NP (DT:[392..396] both) (NNS:[398..403] cases)))
      (,:[403..404] ,)
      (NP-SBJ (DT:[405..408] the) (NNS:[409..414] cells))
      (VP (VBD:[415..423] acquired)
        (NP (JJ:[424..428] long) (NN:[429..433] cell) (NNS:[434..443] processes))))
    (CC:[444..447] and)
    (S
      (NP-SBJ-1 (DT:[448..451] the) (NN:[452..456] cell) (NN:[457..463] growth))
      (VP (VBD:[464..467] was)
        (ADVP (RB:[468..477] partially))
        (VP (VBN:[479..488] inhibited)
          (NP-1 (-NONE-:[488..488] *)))))
    (.:[488..489] .)))

;sentence 5 Span:490..623
;Treatment with RA or TPA resulted in an increased neuron-specific  enolase
;activity, relative to the total cellular enolase activity.
;[557..564]:gene-protein:"enolase"
;[606..613]:gene-protein:"enolase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[490..499] Treatment))
      (PP (IN:[500..504] with)
        (NP (NN:[505..507] RA) (CC:[508..510] or) (NN:[511..514] TPA))))
    (VP (VBD:[515..523] resulted)
      (PP-CLR (IN:[524..526] in)
        (NP
          (NP (DT:[527..529] an) (VBN:[530..539] increased)
            (ADJP (NN:[540..546] neuron) (HYPH:[546..547] -)
                  (JJ:[547..555] specific))
            (NN:[557..564] enolase) (NN:[565..573] activity))
          (,:[573..574] ,)
          (ADJP (JJ:[575..583] relative)
            (PP (TO:[584..586] to)
              (NP (DT:[587..590] the) (JJ:[591..596] total)
                  (JJ:[597..605] cellular) (NN:[606..613] enolase)
                  (NN:[614..622] activity)))))))
    (.:[622..623] .)))

;sentence 6 Span:624..800
;At the  optimal concentration, TPA induced a 200-fold increase in the
;concentration of  noradrenalin, whereas in RA-treated cells the corresponding
;increase was only  fourfold.
(SENT
  (S
    (PP (IN:[624..626] At)
      (NP (DT:[627..630] the) (JJ:[632..639] optimal)
          (NN:[640..653] concentration)))
    (,:[653..654] ,)
    (NP-SBJ (NN:[655..658] TPA))
    (VP (VBD:[659..666] induced)
      (NP
        (NP (DT:[667..668] a)
          (QP (CD:[669..672] 200) (HYPH:[672..673] -) (JJ:[673..677] fold))
          (NN:[678..686] increase))
        (PP (IN:[687..689] in)
          (NP
            (NP (DT:[690..693] the) (NN:[694..707] concentration))
            (PP (IN:[708..710] of)
              (NP (NN:[712..724] noradrenalin))))))
      (,:[724..725] ,)
      (SBAR-ADV (IN:[726..733] whereas)
        (S
          (PP (IN:[734..736] in)
            (NP
              (ADJP (NN:[737..739] RA) (HYPH:[739..740] -)
                    (VBN:[740..747] treated))
              (NNS:[748..753] cells)))
          (NP-SBJ (DT:[754..757] the) (VBG:[758..771] corresponding)
                  (NN:[772..780] increase))
          (VP (VBD:[781..784] was)
            (ADJP-PRD (RB:[785..789] only) (JJ:[791..799] fourfold))))))
    (.:[799..800] .)))

;sentence 7 Span:801..967
;Cells treated with a combination of RA and TPA were morphologically 
;differentiated and growth inhibited and had a high relative activity of 
;neuron-specific enolase.
;[959..966]:gene-protein:"enolase"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[801..806] Cells))
      (VP (VBN:[807..814] treated)
        (NP (-NONE-:[814..814] *))
        (PP (IN:[815..819] with)
          (NP
            (NP (DT:[820..821] a) (NN:[822..833] combination))
            (PP (IN:[834..836] of)
              (NP (NN:[837..839] RA) (CC:[840..843] and) (NN:[844..847] TPA)))))))
    (VP
      (VP (VBD:[848..852] were)
        (ADJP-PRD
          (ADJP (RB:[853..868] morphologically) (VBN:[870..884] differentiated))
          (CC:[885..888] and)
          (ADJP (NN:[889..895] growth) (VBN:[896..905] inhibited))))
      (CC:[906..909] and)
      (VP (VBD:[910..913] had)
        (NP
          (NP (DT:[914..915] a) (JJ:[916..920] high) (JJ:[921..929] relative)
              (NN:[930..938] activity))
          (PP (IN:[939..941] of)
            (NP
              (ADJP (NN:[943..949] neuron) (HYPH:[949..950] -)
                    (JJ:[950..958] specific))
              (NN:[959..966] enolase))))))
    (.:[966..967] .)))

;sentence 8 Span:968..1091
;The increase in the concentration of noradrenalin  induced by TPA was
;inhibited by RA in a concentration-dependent fashion.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[968..971] The) (NN:[972..980] increase))
      (PP (IN:[981..983] in)
        (NP
          (NP (DT:[984..987] the) (NN:[988..1001] concentration))
          (PP (IN:[1002..1004] of)
            (NP
              (NP (NN:[1005..1017] noradrenalin))
              (VP (VBN:[1019..1026] induced)
                (NP (-NONE-:[1026..1026] *))
                (PP (IN:[1027..1029] by)
                  (NP-LGS (NN:[1030..1033] TPA)))))))))
    (VP (VBD:[1034..1037] was)
      (VP (VBN:[1038..1047] inhibited)
        (NP-1 (-NONE-:[1047..1047] *))
        (PP (IN:[1048..1050] by)
          (NP (NN:[1051..1053] RA)))
        (PP (IN:[1054..1056] in)
          (NP (DT:[1057..1058] a)
            (ADJP (NN:[1059..1072] concentration) (HYPH:[1072..1073] -)
                  (JJ:[1073..1082] dependent))
            (NN:[1083..1090] fashion)))))
    (.:[1090..1091] .)))

;sentence 9 Span:1093..1214
;However, despite this result there seemed to be no general antagonistic
;effect  of RA on the TPA-induced differentiation.
(SENT
  (S
    (ADVP (RB:[1093..1100] However))
    (,:[1100..1101] ,)
    (PP (IN:[1102..1109] despite)
      (NP (DT:[1110..1114] this) (NN:[1115..1121] result)))
    (NP-SBJ (EX:[1122..1127] there))
    (VP (VBD:[1128..1134] seemed)
      (S
        (NP-SBJ (-NONE-:[1134..1134] *))
        (VP (TO:[1135..1137] to)
          (VP (VB:[1138..1140] be)
            (NP-PRD
              (NP (DT:[1141..1143] no) (JJ:[1144..1151] general)
                  (JJ:[1152..1164] antagonistic) (NN:[1165..1171] effect))
              (PP (IN:[1173..1175] of)
                (NP (NN:[1176..1178] RA)))
              (PP (IN:[1179..1181] on)
                (NP (DT:[1182..1185] the)
                  (ADJP (NN:[1186..1189] TPA) (HYPH:[1189..1190] -)
                        (VBN:[1190..1197] induced))
                  (NN:[1198..1213] differentiation))))))))
    (.:[1213..1214] .)))

;sentence 10 Span:1215..1346
;The phenotypes of the cells treated by  RA, TPA, or the combination of RA and
;TPA, did, on the other hand, differ from  each other.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1215..1218] The) (NNS:[1219..1229] phenotypes))
      (PP (IN:[1230..1232] of)
        (NP
          (NP (DT:[1233..1236] the) (NNS:[1237..1242] cells))
          (VP (VBN:[1243..1250] treated)
            (NP (-NONE-:[1250..1250] *))
            (PP-MNR (IN:[1251..1253] by)
              (NP
                (NP (NN:[1255..1257] RA))
                (,:[1257..1258] ,)
                (NP (NN:[1259..1262] TPA))
                (,:[1262..1263] ,) (CC:[1264..1266] or)
                (NP
                  (NP (DT:[1267..1270] the) (NN:[1271..1282] combination))
                  (PP (IN:[1283..1285] of)
                    (NP (NN:[1286..1288] RA) (CC:[1289..1292] and)
                        (NN:[1293..1296] TPA))))))))))
    (,:[1296..1297] ,)
    (VP (VBD:[1298..1301] did) (,:[1301..1302] ,)
      (PP (IN:[1303..1305] on)
        (NP (DT:[1306..1309] the) (JJ:[1310..1315] other) (NN:[1316..1320] hand)))
      (,:[1320..1321] ,)
      (VP (VB:[1322..1328] differ)
        (PP (IN:[1329..1333] from)
          (NP (DT:[1335..1339] each) (JJ:[1340..1345] other)))))
    (.:[1345..1346] .)))

;sentence 11 Span:1347..1451
;Our results suggest that RA and TPA induce the SH-SY5Y cells to 
;differentiate along different pathways.
(SENT
  (S
    (NP-SBJ (PRP$:[1347..1350] Our) (NNS:[1351..1358] results))
    (VP (VBP:[1359..1366] suggest)
      (SBAR (IN:[1367..1371] that)
        (S
          (NP-SBJ (NN:[1372..1374] RA) (CC:[1375..1378] and)
                  (NN:[1379..1382] TPA))
          (VP (VBP:[1383..1389] induce)
            (NP (DT:[1390..1393] the) (NN:[1394..1401] SH-SY5Y)
                (NNS:[1402..1407] cells))
            (S-ADV
              (NP-SBJ (-NONE-:[1407..1407] *))
              (VP (TO:[1408..1410] to)
                (VP (VB:[1412..1425] differentiate)
                  (PP (IN:[1426..1431] along)
                    (NP (JJ:[1432..1441] different) (NNS:[1442..1450] pathways))))))))))
    (.:[1450..1451] .)))

;section 12 Span:1455..1499
;PMID: 6467378 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1455..1459] PMID) (::[1459..1460] :) (CD:[1461..1468] 6467378)
        (NN:[1469..1470] -LSB-) (NNP:[1470..1476] PubMed) (::[1477..1478] -)
        (NN:[1479..1486] indexed) (IN:[1487..1490] for)
        (NNP:[1491..1499] MEDLINE-RSB-)))
